Oryn Therapeutics, Inc.
Vacaville, CA · Biotech · Private
Macrocyclic peptide drugs (Orynotides) for treating systemic candidiasis caused by multidrug-resistant Candida species
oryntherapeutics.com →- Grants
- $9.2M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20152016201720182019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · First-in-Class Macrocyclic Peptide Therapeutic For Rheumatoid Arthritis | $1,142,534 | |
| Federal grant | Department of Health and Human Services · Phase II · First-in-Class Macrocyclic Peptide Therapeutic For Rheumatoid Arthritis | $1,495,283 | |
| Federal grant | Department of Health and Human Services · Phase II · First-in-Class Macrocyclic Peptide Therapeutic For Rheumatoid Arthritis | $352,749 | |
| Federal grant | Department of Health and Human Services · Phase II · Cyclic Orynotides for Systemic MDR Candidiasis | $284,978 | |
| Federal grant | Department of Health and Human Services · Phase II · Cyclic Orynotides for Systemic MDR Candidiasis | $998,632 | |
| Federal grant | Department of Health and Human Services · Phase II · Cyclic Orynotides for Systemic MDR Candidiasis | $2,973,531 | |
| Federal grant | Department of Health and Human Services · Phase II · Cyclic Orynotides for Systemic MDR Candidiasis | $991,551 | |
| Federal grant | Department of Health and Human Services · Phase II · Cyclic Orynotides for Systemic MDR Candidiasis | $983,348 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3290 | Fortify Therapeutics | — | — |
| 3291 | Jade Biosciences | — | — |
| 3292 | NAVIGEN, INC. | — | — |
| 3293 | Oryn Therapeutics, Inc. | — | — |
| 3294 | Inflamma Therapeutics, LLC | — | — |
| 3295 | CELLCHORUS INC. | — | — |
| 3296 | Viking Therapeutics, Inc. | — | $3.7M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.